The current status of reversal therapy in Japan for elderly patients with head injury treated with antithrombotic agents: A prospective multicenter observational study
- PMID: 38318008
- PMCID: PMC10839600
- DOI: 10.1016/j.heliyon.2024.e25193
The current status of reversal therapy in Japan for elderly patients with head injury treated with antithrombotic agents: A prospective multicenter observational study
Abstract
Background: Acute exacerbation of head injury in elderly patients due to use of antithrombotic agents has become a concern in countries with aging populations. Reversal agents are recommended for treatment, but its usage is unclear. Therefore, we conducted a prospective observational study in this patient population to monitor usage of reversal therapy.
Methods: The subjects were 721 elderly patients aged ≥65 years old who were hospitalized in 15 centers from December 2019 to May 2021. Patients were divided into groups who did not receive antithrombotic agents (Group A), who received antithrombotic agents, but did not receive reversal therapy (Group B), and were treated with antithrombotic agents and reversal therapy (Group C). Age, gender, mechanism of injury, neurologic and imaging findings on admission, clinical course after admission and surgery, outcomes and complications were compared among these groups. Time from injury to reversal therapy was examined based on outcomes to investigate trends in the timing of administration of the reversal agent.
Results: Acute exacerbation during the clinical course occurred in 9.8 %, 15.8 % and 31.0 % of cases in Groups A, B and C, respectively, and differed significantly among the groups. On head CT, the incidences of hematoma were 35.7 %, 36.5 % and 60.4 %, respectively, with this incidence being significantly higher in Group C; and the respective rates of craniotomy were 18.8 %, 14.0 % and 50.9 %, again with this rate being significantly higher in Group C. The good outcome and mortality rates were 57.1 %, 52.5 % and 35.8 %, and 14.5 %, 18.0 % and 24.5 %, respectively, and both were poorest in Group C. Times from injury to treatment with a reversal agent were significantly shorter in patients without compared to those with acute exacerbation (405.9 vs. 880.8 min) and in patients with favorable outcomes compared to those with unfavorable outcomes (261.9 vs. 543.4 min).
Conclusion: Similarly to previous studies, the incidence of acute exacerbation was increased by use of antithrombotic agents. These results suggest that patients in Japan who require hematoma evacuation due to symptom exacerbation tend to be treated with reversal agents. Although it is difficult to assess the efficacy of reversal therapy from this study, earlier treatment with reversal agents before the occurrence of acute exacerbation may be useful to improve outcomes.
Keywords: Acute exacerbation; Antithrombotic agents; Reversal therapy; Traumatic brain injury.
© 2024 The Authors.
Conflict of interest statement
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Eiichi Suehiro reports financial support was provided by 10.13039/100008322CSL Behring K.K. United States. Eiichi Suehiro reports a relationship with Boehringer Ingelheim, Germany that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10839600/bin/gr1.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10839600/bin/gr2.gif)
Similar articles
-
Risk of Deterioration of Geriatric Traumatic Brain Injury in Patients Treated with Antithrombotic Drugs.World Neurosurg. 2019 Jul;127:e1221-e1227. doi: 10.1016/j.wneu.2019.04.108. Epub 2019 Apr 19. World Neurosurg. 2019. PMID: 31009773
-
Effects of dual antiplatelet therapy (DAPT) compared to single antiplatelet therapy (SAPT) in patients with traumatic brain injury.Clin Neurol Neurosurg. 2024 Jul 1;244:108418. doi: 10.1016/j.clineuro.2024.108418. Online ahead of print. Clin Neurol Neurosurg. 2024. PMID: 38959785
-
The implications of antithrombotic agents on subdural hematoma evacuation: what does "reversal" truly entail?Neurosurg Focus. 2023 Oct;55(4):E5. doi: 10.3171/2023.7.FOCUS23354. Neurosurg Focus. 2023. PMID: 37778049
-
Anticoagulation and Antiplatelet Agent Resumption Timing following Traumatic Brain Injury.Korean J Neurotrauma. 2023 Sep 12;19(3):298-306. doi: 10.13004/kjnt.2023.19.e42. eCollection 2023 Sep. Korean J Neurotrauma. 2023. PMID: 37840609 Free PMC article. Review.
-
Effect of Pre-Management Antithrombotic Agent Use on Outcome after Traumatic Acute Subdural Hematoma in the Elderly: A Systematic Review.J Neurotrauma. 2023 Apr;40(7-8):635-648. doi: 10.1089/neu.2022.0052. Epub 2023 Jan 5. J Neurotrauma. 2023. PMID: 36266996 Review.
References
-
- Cabinet Office Japan Annual report on the aging society. 2021 https://www8.cao.go.jp/kourei/english/annualreport/2021/pdf/2021.pdf
LinkOut - more resources
Full Text Sources